Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. TSH Biopharm's Cost of Goods Sold for the
three
months ended in Dec. 2025 was NT$178 Mil. TSH Biopharm's Average Total Inventories for the quarter that ended in Dec. 2025 was NT$174 Mil.
TSH Biopharm's Inventory Turnover for the quarter that ended in Dec. 2025 was 1.02.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
TSH Biopharm's Days Inventory for the
three
months ended in Dec. 2025 was 89.18.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
TSH Biopharm's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.49.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
TSH Biopharm's Days Inventory for the
three
months ended in Dec. 2025 is calculated as:
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
TSH Biopharm's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
TSH Biopharm Inventory Turnover Related Terms
TSH Biopharm Inventory Turnover Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm (ROCO:8432) has a Inventory Turnover of 1.02 as of Dec. 2025. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on TSH Biopharm and its competitors.
Is TSH Biopharm's Inventory Turnover too high?
TSH Biopharm's current Inventory Turnover is 1.02. Overall, TSH Biopharm has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Inventory Turnover compare to ZTS and UTHR?
TSH Biopharm's Inventory Turnover of 1.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Drug Manufacturers company?
A good Inventory Turnover depends on the Drug Manufacturers industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on TSH Biopharm and its competitors. TSH Biopharm's current Inventory Turnover is 1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$79.07, compared to a current price of NT$50.30 — trading 36.4% below its estimated fair value. The current Inventory Turnover is 1.02. TSH Biopharm's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Inventory Turnover is 1.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.30 is trading 36.4% below its estimated GF Value™ of NT$79.07.
GuruFocus considers TSH Biopharm to be Significantly Undervalued.
Key valuation signals for ROCO:8432:
Inventory Turnover: 1.02
GF Value™: NT$79.07 vs. price of NT$50.30 (36.4% below fair value)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
86GF Score
Get the complete analysis for ROCO:8432
Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
